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ABSTRACT 
A substantial and increasing body of clinical evidence supports the role of specific strains and 
mixtures  of  probiotics  in  the  prevention  and  treatment  of  certain  diseases.  Several  general 
mechanisms  of  action  have  been  proposed,  including  supporting  repair  of  hyperpermeable 
epithelial barriers, interfering with infection by pathogens, and restoring a healthful balance of 
commensal microbes to affect metabolism. Emerging evidence supports an additional role of 
probiotics  as  important  modulators  of  immune  system  responses,  including  inflammation,  at 
mucosal surfaces. In particular, by preventing or repairing ‘leaky’ epithelial barriers, probiotics 
can  indirectly  affect  the  inflammatory  response  by  negating  the  source  of  pro-inflammatory 
stimuli associated with low-grade endotoxemia. They also enhance production of short chain 
fatty  acids  with  anti-inflammatory  properties  (e.g.  butyrate)  as  well  as  increase  synthesis  of 
antimicrobial  peptides  that  influence  inflammation  resolution  pathways  in  the  mucosa. 
Furthermore, probiotics and some of their secreted metabolic products can act as ligands for 
innate immune system receptors, directly influencing key pro-inflammatory pathways. They also 
stimulate the differentiation and activity of important immune cells (e.g., dendritic cells, T cells), 
and subsequently increase production of important regulatory cytokines, including interleukin-10 
(IL-10) and transforming growth factor-beta (TGF-. Finally, there are limited but increasing 
animal  studies  and  clinical  trials  demonstrating  probiotics  do  affect  common  biomarkers  of 
inflammation, including C-reactive protein, as well as signs and symptoms of the associated 
diseases suggesting they can have therapeutic benefit in the treatment of chronic inflammatory 
disease. 
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INTRODUCTION  
Our understanding of the beneficial roles of commensal microorganisms in sustaining human 
health has increased dramatically in recent times.  It is evident a prolonged disruption in the Functional Foods in Health and Disease 2014; 4(7):299-311                                                            Page 300 of 311 
normal ecology of commensal microflora (often termed dysbiosis) can contribute to different 
diseases  through  a  number  of  mechanisms.  For  example,  a  reduced  diversity  of  ‘healthy’ 
microbiota  and  subsequent  opportunistic  overgrowth  of  potentially  pathogenic  commensal 
bacteria and fungi alters signaling to the immune system. This results in abnormal activation of 
certain immune cells (e.g., Th1, Th17, gamma delta T (T) cells and innate lymphocytes) and 
repression of certain regulatory mechanisms (e.g., reduction of the activity and number of Treg 
and  Tr1  cells,  reduced  immunoglobulin  A  (IgA)  synthesis  and  lowered  levels  of  major 
suppressive cytokines such as IL-10 and TGF-) [1]. In general, the immunological outcome of 
dysbiosis is a shift away from the normal state of tolerance to an abnormal state of heightened 
reactivity  towards  commensal  microbiota  and  dietary  substances,  resulting  in  chronic 
inflammation. There is a substantial and increasing body of scientific literature demonstrating 
that  supplementation  with  probiotics  can  help  treat  dysbiosis,  restore  a  healthy  microbial 
ecology, and modulate the chronic inflammatory processes that can lead to disease.  
 
REVIEW 
Probiotics  can  help  regulate  inflammation  in  a  number  of  ways,  but  this  paper  will  focus 
primarily  on:  1)  indirect  effects,  by  maintaining  or  repairing  epithelial  barriers,  enhancing 
production of short chain fatty acids with anti-inflammatory properties (e.g., butyrate) as well as 
increasing synthesis of antimicrobial peptides that influence inflammation resolution pathways in 
the mucosa and 2) direct effects, by binding innate immune system receptors and triggering 
pathways that affect the production of cytokines associated with inflammation. 
 
Indirect effects: 1) Repair of hyperpermeable epithelial barriers 
A hyperpermeable epithelial barrier in the gastrointestinal tract is proposed as a major cause of 
chronic inflammation in a recently described pathophysiological process termed low-grade or 
subclinical  endotoxemia.  This  is  also  termed  metabolic  endotoxemia  if  the  cause(s)  of  the 
hyperpermeability  are  metabolic  in  origin,  including  a  high-fat  diet.  In  general,  low-grade 
endotoxemia means there is abnormal translocation of macromolecules, including Gram-negative 
bacteria across the barrier, resulting in the lipopolysaccharide (LPS) (also termed endotoxin) 
portion of their cell wall, entering circulation to act as a constant low-level pro-inflammatory 
stimulus. This is in contrast to the most commonly recognized abnormal translocation of LPS, 
where  a  relatively  large  amount  (>10-200  ng/ml)  enters  systemic  circulation  to  cause 
overwhelming  systemic  inflammation  and  the  serious  and  potentially  fatal  condition  termed 
sepsis [2]. The medical consequences of this persistent ‘trickle’ of LPS (e.g., 1pg-100pg/ml) are 
potentially enormous with metabolic endotoxemia recently referred to as “one of the key culprits 
in  provoking  a  non-resolving  low-grade  inflammation”  [2].  Indeed,  many  different  chronic 
diseases, including obesity [3], diabetes [4], fatty liver disease and nonalcoholic steatohepatitis 
[5], atherosclerosis, Parkinson’s disease [6], and cancer cachexia [7], are now correlated with 
metabolic endotoxemia.  
Treatment  of  low-grade  endotoxemia  requires  a  comprehensive  clinical  approach  that 
includes alteration of certain dietary choices and lifestyle behaviors, inclusion of medications 
with  anti-inflammatory  and/or  drainage  properties,  but  most  importantly,  repair  of  damaged 
epithelial  barriers.  A  number  of  different  natural  health  products  will  help  repair  a Functional Foods in Health and Disease 2014; 4(7):299-311                                                            Page 301 of 311 
hyperpermeable  epithelial  barrier,  including  glutamine  [8],  quercetin,  zinc  [9]  (e.g.,  zinc 
carnosine  [10])  and  different  herbal  medicines,  but  undoubtedly the most  studied product  is 
probiotics.  
There  are  a  number  of  mechanisms  whereby  certain  probiotic  strains  can  improve  the 
structure and function of intestinal epithelial barriers, including buttressing the physical barrier, 
increasing mucin production, promoting production of antimicrobial peptides and heat shock 
proteins, attenuating the negative effect of pathogenic microorganisms, and modulating signaling 
pathways that affect cell proliferation and survival [11, 12].  For a diagrammatic representation 
of the various mechanisms of action of probiotics refer to [11, 12]. Of particular interest is the 
ability of specific probiotic strains to significantly decrease tumor necrosis factor alpha (TNF-
 a pro-inflammatory cytokine that causes leaky barriers by directly impairing the 
integrity of the tight junctional complexes between epithelial cells. Other probiotic strains bolster 
mucosal membrane integrity by directly affecting expression of one or more of the important 
tight junctional proteins (e.g., zonulin-1, occludin and cingulin) [16, 17]. Various other cellular 
and molecular mechanisms (eg. release of metabolites and bioactive molecules, suppression of 
oxidative  stress,  interference  with  inflammatory  pathways,  increase  expression  of  mucins, 
augment levels of IgA) are used by different probiotic strains to help protect and repair epithelial 
barriers [18, 19]. Several different probiotics including Lactobacillus species (eg. L. rhamnosus 
GG, L. plantarum DSM 9843, L reuteri R2LC, L casei DN-114001, L. paracasei NCC2461), 
Bifidobacterium infantis, Saccharomyces boulardii and S. cerevisae UFMG 905 and Escherichia 
coli Nissle 1917 have been shown to protect and repair epithelial barriers in vitro [18, 19]. 
There also are a number of animal studies [20, 21] and clinical trials [22, 23, 24, 25, 26, 27] 
demonstrating the efficacy of different probiotics in repairing or preventing damage to epithelial 
barriers caused by different diseases or other stressors. 
 
Indirect effects: 2) Increase production of short chain fatty acids including butyrate 
Another indirect effect of probiotics on inflammation occurs via their ability to ferment certain 
types of fiber, thus increasing the production of short chain fatty acids, such as: propionate, 
acetic acid, and butyrate. Butyrate is particularly important as a modulator of inflammation, with 
anti-inflammatory  effects  demonstrated  in  intestinal  epithelial  cells,  macrophages,  and 
leukocytes  [28].  For  example,  butyrate  acts  as  an  important  signaling  molecule,  influencing 
pathways that block NF-B-induced increases in pro-inflammatory cytokines by a number of 
different mechanisms [11].  Butyrate also regulates the production of certain cytokines (e.g., 
TNF-, IL-2, IL-6, IL-10), eicosanoids and chemokines from leukocytes, and affects their ability 
to migrate to sites of inflammation [14].  Furthermore, butyrate is an important inhibitor of 
histone deacetylase and has the potential to regulate expression of numerous genes, including 
those that encode important inflammatory mediators, i.e., nitric oxide (NO), IL-6 and IL-12 [29]. 
It also was recently shown to induce the differentiation and expansion of regulatory T cells not 
only in the colon [30] but also in the periphery [31], suggesting butyrate plays an important role 
in maintaining the balance between tolerance and hyper-reactivity. Finally, butyrate is a primary 
fuel  source  for  colonocytes,  and  therefore  helps  maintain  epithelial  barriers  in  a  number  of 
different ways [32]. This evidence that butyrate also has important anti-inflammatory properties Functional Foods in Health and Disease 2014; 4(7):299-311                                                            Page 302 of 311 
highlights the potential of using a carefully selected mixture of probiotic strains and compatible 
prebiotics (i.e. to formulate synbiotics) to maximize therapeutic efficacy [33].  
 
Indirect effects: 3) Promote synthesis of antimicrobial peptides 
Antimicrobial peptides (AMPs) are a group of small amphipathic peptides (e.g., defensins and 
cathelicidins) found in multicellular organisms such as plants and animals [34] and is produced 
by a wide variety of different cell types, including epithelial cells, leukocytes, intestinal Paneth 
cells [35] and keratinocytes [36, 37]. They were originally recognized and named for their role as 
potent  broad-spectrum  natural  antimicrobials,  providing  a  first  line  of  defense  at  mucosal 
barriers, including those in the gastrointestinal and pulmonary tract [38]. Since their discovery, 
numerous  additional  functions  have  been  determined,  including  important  roles  as  immune 
signaling  molecules  that  influence  diverse  functions,  such  as  wound  repair,  expression  of 
different  chemokines  and  cytokines,  recruitment  of  leukocytes,  chemotaxis  of  mast  cells, 
modulation of dendritic cell function and even modulation of adaptive immunity [39, 40]. In fact, 
AMPs  are involved in  such a widespread diversity of signaling  that  it is proposed they  are 
“poorly named, antimicrobial peptides are multifunctional pillars around which the innate and 
adaptive immune response has evolved” [41].  Recently it was shown that these AMPs also act in 
prime inflammation resolution in the mucosa [42], suggesting they are part of an additional 
endogenous  local  pathway  used  to  control  an  acute  inflammatory  response,  bringing  the 
associated inflamed tissue back to  homeostasis. There  are  a number of different  substances, 
including Vitamin D [43, 44], certain amino acids [45], butyrate [46], and probiotics [47], that 
are recognized as potent inducers of the synthesis and activity of AMPs.  
Probiotics including Escherichia coli Nissle 1917, Lactobacillus fermentum PZ1162 and the 
mixture VSL# 3 were demonstrated to induce the secretion of AMP human beta-defensin -2 
through pro-inflammatory pathways that involved the transcription factors NF-B and AP-1 as 
well as MAPKs [47].  Several other types of AMPs including various bacteriocins are induced by 
various strains of probiotics (eg. L. salivarius DPC6005, L. salivarius UCC118, L. plantarum 
DDEN 11007, L. plantarum C11, L. lactis DPC3147) and demonstrated to have multiple roles in 
colonization, microbicidal activity as well as other signaling functions [48].  Although there is a 
need for further research, enhancing synthesis  and secretion of AMPs  might prove to be an 
additional indirect pathway whereby probiotics could help regulate an inflammatory response.   
 
Direct effects: 1) Act as ligands for innate immune system receptors such as Toll-like receptors 
and nucleotide-binding oligomerization domain receptors 
Probiotics also can have direct effects on the inflammatory response by acting as ligands for 
specific members of a large family of innate immune system receptors termed Toll-like receptors 
(TLRs), thereby influencing important signaling pathways, including NF-B, mitogen-activated 
protein kinase (MAPK), phosphoinositide-3-kinase-protein kinase B/Akt (PI3K-PKB/Akt), and 
peroxisome proliferator-activated receptor gamma (PPAR[11].  TLR-2 and TLR-4 activation 
by probiotic microorganisms are recognized as particularly important receptors mediating the 
direct influence of probiotic and commensal bacteria on inflammatory signaling pathways [12, 
49]; TLR-9 also is identified as an important receptor for mediating the anti-inflammatory effect 
of certain probiotic strains [12, 50].   Functional Foods in Health and Disease 2014; 4(7):299-311                                                            Page 303 of 311 
Recent evidence suggests that some species of probiotics may release low molecular weight 
substances  that  can  cross  the  epithelial  cell  membrane  to  interact  with  specific  members  of 
another large group of intracellular innate immune system receptors termed nucleotide-binding 
oligomerization domain receptors (NLRs) [12]. Triggering the downstream pathways associated 
with activation of NLRs represents another method whereby probiotics can affect inflammasome 
assembly and NF-B associated signaling, thus the inflammatory response. 
The  ability  of  probiotics  to  influence  NF-B  and  PPARsignaling  pathways  would 
especially  have  widespread  effects  on  inflammation,  as  these  two  transcription  factors  are 
recognized  as  critically  important  intracellular  hubs  at  the  intersection  of  many  different 
pathways leading to production of numerous proinflammatory signals, including cytokines and 
chemokines.  Activation  of  TLRs  and  NLRs  also  leads  to  assembly  of  inflammasomes  (i.e., 
intracellular molecular platforms found in many cells that have a number of different regulatory 
functions, but are particularly responsible for activating the enzyme caspase-1 involved in the 
final maturation of the key pro-inflammatory cytokine IL-1 and IL-18) [51].  
The effects of probiotics are strain specific, thus not all probiotics will have similar effects 
on each signaling pathway. A detailed summary of the current research on various probiotics and 
the  specific  signaling  pathway  they  affect  in  different  model  systems  has  been  published 
elsewhere [11] and will not be included in this paper.  In sum, the binding of probiotics and 
commensal microflora to innate immune systems receptors such as TLRs and NLRs would help 
regulate major intracellular pathways that help maintain the homeostatic balance between pro-
inflammatory and anti-inflammatory responses at mucosal surfaces. 
It is important to note that some probiotics (e.g., Bifidobacterium lactis BB12, Bacteroides 
vulgatus) also stimulate NF-B controlled signaling by a number of different mechanisms [11], 
suggesting they have pro-inflammatory effects. This pro-inflammatory effect of some probiotics 
could  be  beneficial,  as  suggested  by  current  scientific  evidence  that  a  certain  low  level  of 
inflammation could have physiological benefits including maintenance of epithelial barriers and 
‘priming’  of  immune  system  responses.  Furthermore,  the  immunostimulatory  phenotypes  of 
commensal bacteria and probiotics might serve an important purpose of promoting host defense 
against pathogens..  
 
Direct effects: 2) Influence maturation and development of important immune cells such as 
dendritic cells and T cells  
In addition to their ability to affect intestinal epithelial cells and macrophages, probiotics also 
help influence the differentiation and function of a number of other immune cells associated with 
an inflammatory response, including dendritic cells as well as T cells (refer to [11, 12] for a 
diagrammatic representation). The ability of probiotics to affect the maturation, survival and 
function of dendritic cells [11] has widespread implications, because these professional antigen-
presenting  cells  play  key  roles  at  mucosal  surfaces  in  maintaining  tolerance  to  commensal 
microbiota and innocuous food antigens. They also are an important source of cytokines that 
help promote differentiation of naive T cells into Th1, Th2, Th17 or T regulatory cells, thus the 
appropriate cell-mediated or humoral immune response [11].  Finally, different probiotic strains 
and species of beneficial microbes also influence the development and survival of different types Functional Foods in Health and Disease 2014; 4(7):299-311                                                            Page 304 of 311 
of regulatory T cells, including Th3, Tr1, CD4+CD25+ regulatory, CD8+ suppressor and T 
cells [11],
 suggesting they can have a widespread role in maintaining intestinal homeostasis and 
the  balance  between  oral  tolerance  and  reactivity  to  ingested  food  antigens  as  well  as  to 
commensal microbes.  
 
Direct effects: 3) Influence synthesis of the important regulatory cytokines IL-10 and TGF- 
Different  populations  of  regulatory  T  cells  exert  their  inflammation-modulating  effect  by 
secreting specific cytokines, including IL-10 (which strongly suppresses a Th-1 dominant pro-
inflammatory  response)  or  more  regulatory  cytokines  such  as  TGF-  (which  promotes 
development of regulatory T cells). Certain probiotic strains help regulate inflammation via their 
enhanced ability to influence the secretion of these important cytokines [11]; refer to [11, 12] for 
a diagrammatic representation
.  This effect has been demonstrated, in vitro [52,53] and in vivo, in 
various animal models [54, 55, 56, 57] and clinical studies [58].  
 
Clinically meaningful effects on inflammation? 
There  also  are  a  limited  number  of  studies  demonstrating  that  supplementation  with  certain 
probiotics significantly reduced hs-CRP levels in adults that were healthy [59], pregnant [60], 
critically ill [61] or had inflammatory bowel disease [62] as well as other inflammatory disorders 
(e.g., ulcerative colitis, chronic fatigue syndrome and psoriasis) [63] and type 2 diabetes [64], 
suggesting that they could have a widespread anti-inflammatory effect that is clinically relevant. 
Considerable heterogeneity exists in the clinical trial design published to date making it 
difficult  to  determine  the  exact  dosing  and  strains  of  probiotics  needed  to  ensure  maximal 
therapeutic benefits in specific clinical conditions including inflammatory disease.  For example, 
in the trials listed above there were major differences in study populations, types and daily dose 
of probiotics used, type of placebo, length of study as well as the delivery medium (Table 1).  
 
Table 1: Summary of Clinical trials measuring effects of Probiotics on the inflammatory marker 
CRP 
 
Reference  Study design  Study 
population & 
characteristics 
Probiotic strains used  Daily dose 
provided 
Delivery 
medium 
Placebo 
used 
Length 
of study 
[59] 
Kekkonen 
RA, 
Lummela 
N et al. 
2008 
Randomized, 
double-blind 
and placebo-
controlled 
parallel 
group 
intervention; 
Single strains 
given to 
different 
groups and 
compared to 
placebo 
Healthy adults 
(n=68) 
Mean age 44 
years; mean 
BMI 24kg/m
2 
Lactobacillus rhamnosus GG  
ATCC 53103 (n=13)  
Bifobacterium animalis ssp. 
lactis Bb12 (n=16) 
Probionibacterium 
freudenreichii spp shermanii 
JS (n=17) 
1.6 X 10 
10 cfu 
 
3.5 X 10 
10 cfu 
 
3.3 X 10 
10 cfu 
250 mL 
milk-based 
fruit drink 
Milk-
based fruit 
drink 
without 
probiotics 
(n=16) 
3 weeks 
[60] 
Asemi Z, 
Jazayeri S 
et al. 2011 
Randomized 
clinical trial; 
2 probiotic 
species given 
and 
compared to 
Healthy 
pregnant 
women in 3
rd 
trimester 
(n=70) 
Bifidobacterium aminalis ssp 
lactis Bb-12 
Lactobacillus acidophilus 
LA-5 
(n=37) 
 
200 g of 
probiotic yogurt 
containing 10
7 
CFU/ g of each 
(i.e. 2X 10 
9 cfu) 
Yogurt 
prepared 
with starter 
culture of 
Streptococc
us 
Yogurt 
without 
probiotics 
(n=33) 
9 weeks Functional Foods in Health and Disease 2014; 4(7):299-311                                                            Page 305 of 311 
 
Furthermore, many studies do not list the strains of probiotics used in the intervention, even 
though it is becoming increasingly clear that not all strains have similar effects even if they are 
from the same species. All of these factors (and others) could potentially influence the ability of 
probiotics to control inflammation and therefore, it is difficult at this time to make definitive 
placebo  thermophil
us and 
Lactobacill
us 
bulgaricus  
[61] 
Sanaie S, 
Ebrahimi-
Mamegha
ni M et al., 
2013 
Double-blind 
randomized 
control; 
given 
standard 
treatment 
with or 
without 
multistrain 
probiotic 
VSL#3 
Critically ill 
patients 
admitted to 
ICU, receiving 
enteral nutrition 
(Fresenius 
original fiber)  
(n=40) 
VSL#3: Strains not given 
because “*VSL 
Pharmaceuticals consider the 
strain number proprietary” 
http://www.vsl3.com/discove
r/aboutprobiotics.asp 
Lactobacillus casei, 
Lactobacillus plantarum, L 
acidophilus, Lactobacillus 
delbrueckii subsp. Bulgaricus 
Bifidobacterium longum, 
Bifidobacterium breve, 
Bifidobacterium infantis 
Streptococcus salvarius 
subsp. Thermophilus 
(n=20) 
2X 900 billion  
(i.e. 1.8 X 10 
12 
cfu) 
Standard 
treatment 
without 
placebo 
(n=20) 
None  7 days 
[62] 
Shadnoush 
M, Shaker 
Hosseini R 
et al., 2013 
Randomized, 
comparative 
study; 2 
probiotic 
species given 
and 
compared to 
healthy 
controls 
(n=84) 
IBD patients in 
remission; 
mean age 38 
years; mean 
BM 24.17 
kg/m
2; 
randomized 
into two groups 
(with probiotics 
(n=86) or 
without 
probiotics 
(n=90)  
NO species or strain 
information given 
Bifidobacterium 
Lactobaccillus 
(n=86) 
250 g yogurt 
containing 10
6 
cfu/ g 
(i.e. 2.5 X 10
8 
cfu) 
1.5% fat 
yogurt (NO 
starter 
culture 
strains 
given) 
Plain 
yogurt 
without 
probiotics 
(n=90) 
8 weeks 
 
[63] 
Groeger 
D, 
O’Mahony 
L et al., 
2013 
 
Randomized 
double-blind, 
placebo-
controlled; 
single strain 
given to 3 
different 
groups and 
compared to 
placebo 
 
Ulcerative 
colitis patients 
(n=22) 
Psoriasis 
patients (n=26) 
CFS patients 
(n= 48) 
Healthy 
controls (n=22) 
 
Bifidobacterium infantis 
35264 
 
1X 10
10 cfu 
 
Oral 
sachets 
 
Maltodext
ran (5g) 
 
6-8 
weeks 
[64] 
Asemi Z, 
Zare Z et 
al. 2013 
Randomized 
double-blind 
placebo 
controlled; 7 
strain 
multispecies 
probiotic 
supplement 
given 
Diabetic 
patients (n=54); 
age 35-70 years 
NO strain information given 
L. acidophilus 
L. casei 
L. rhamnosus 
L. bulgaricus 
Bifidobacterium breve 
B. longum 
Streptococcus thermophilus  
plus 100 mg fructo-
oligosaccharide 
(n=27) 
 
2X 10
9 cfu 
7X 10
9 cfu 
1.5X 10
9 cfu 
2X 10
8 cfu 
2X 10
10 cfu 
7X10
9 cfu 
1.5X10
9 cfu 
 
Oral 
capsules 
Similar 
capsule 
without 
probiotics 
(n=27) 
8 weeks Functional Foods in Health and Disease 2014; 4(7):299-311                                                            Page 306 of 311 
clinical recommendations.  However, in general the range of doses used to alleviate symptoms of 
disease ranges from 100 million cfu/d for Bifidobacterium infantis 35624 to 300 to 450 billion 
cfu  3  times  daily  for  VSL#3  (a  mixture  of  1  strain  of  Streptococcus  thermophilus,  4 
Lactobacillus species, and 3 Bifidobacterium species strains) in various clinical trials [65].  
 
CONCLUSION 
There is sufficient current scientific literature to support supplementation with probiotics as a 
beneficial  addition  to  comprehensive  treatment  of  inflammatory  disease.  Specific  probiotic 
strains  can  help  repair  hyperpermeable  epithelial  barriers  and  therefore,  indirectly  regulate 
inflammation by shutting down potentially important sources of stimuli of chronic inflammation, 
including LPS. They also are important inducers of other molecules that play widespread roles in 
modulating inflammation, including butyrate and AMPs. Furthermore, specific strains and/or 
their components bind TLRs or NLRs to directly influence the activity of various important 
signaling  pathways,  influencing  inflammation  by  promoting  production  of  more  suppressive 
and/or regulatory cytokines such as IL-10 and TGF-. Using a combination of different well-
researched probiotic strains to simultaneously modulate multiple signaling pathways could have 
a profound synergistic or additive effect on controlling and resolving inflammation in a timely 
fashion. 
There is a need for additional preclinical and clinical research to further differentiate the 
optimum dose, posology, and exact strains of probiotics that have the most profound long-term 
effect  on  modulating  the  inflammatory  response.  Additional  complexity  in  developing 
individualized inflammation regulating therapies using probiotics is created by the knowledge 
that different persons have unique endotypes of commensal microbiota as well as the recognition 
that a numerous factors, including age, genetics, use of certain medications, diet, geography and 
even psychological stress, can cause lasting shifts in commensal microbial ecology. Furthermore, 
the different types of diseases and even the phase the patient is in (especially in chronic relapsing 
diseases) will influence the quantity and quality of pro-inflammatory cytokines that need to be 
modulated by probiotics to produce clinically meaningful effects.  Finally, it is unlikely that 
probiotics can act as a stand-alone therapy for treating inflammatory disease; therefore, it will be 
important to further delineate which therapies and medications can be used concomitantly to 
produce the safest and most effective clinical outcome. 
 
List of abbreviations: 
AMPs: antimicrobial peptides 
T: gamma delta T cells 
hsCRP: high-sensitivity C-reactive protein 
IgA: immunoglobulin A 
IL-10: interleukin-10 
LPS: lipopolysaccharide (also termed endotoxin) 
NO: nitric oxide 
NF-B: nuclear factor kappa B 
NLRs: nucleotide-binding oligomerization domain receptors 
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PPAR-: peroxisome proliferator-activated receptor gamma 
PI3K/PKB/Akt: phosphoinositide-3-kinase-protein kinase B 
TGF-: transforming growth factor beta 
TLR: Toll-like receptor 
TNF-: tumor necrosis factor alpha   
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